All News

Lungs ILD

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
RheumNow Podcast square

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
ild.jpg

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Jack Cush, MD

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

Read Article
alveolar hemorrhage acute

Alveolar Hemorrhage and Mortality in Lupus

Jack Cush, MD

Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Fails to Prevent COVID-19

Jack Cush, MD

There is a preponderance and mounting evidence that hydroxychloroquine is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons.

Read Article
covid.corona

Adverse Events with Anti-malarials during the COVID Pandemic

Jack Cush, MD

For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.

Read Article
Lifestyle diet alcohol risk obesity

One-Third Rheumatoid Risk from Lifestyle

Jack Cush, MD

Analysis of the NHANES (National Health and Nutrition Examination Survey) data suggests that one-third of the risk of developing rheumatoid arthritis (RA) in the USA is attributable smoking, obesity and alcohol intake.

Read Article
Other recommendations from Dr Calabrese @CCalabreseDO today @AWIRGROUP Summit. #WomeninRheum education everyone. https://t.co/YahmODVEw2
WOMEN IN RHEUM AWIRGROUP ( View Tweet)
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv

Links:

Dr. John Cush RheumNow ( View Tweet)
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Links:

Dr. John Cush RheumNow ( View Tweet)

While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March. Register to attend today. https://t.co/uwxOVh142F https://t.co/bnittqkhKQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Lung Preservation w/ Tocilizumab in Early Systemic Sclerosis Arthritis & Rheumatology has published the results of a subanalysis from TCZ clinical trials showing that Il-6 inhibition is related with preservation of lung function patients with early SSc. https://t.co/2BwWQWEkri https://t.co/pjVc8YTDwU

Links:

Dr. John Cush RheumNow ( View Tweet)
CTD associated pulmonary HTN has improved sincd 2010. Metanalysis of 11 RCTs (4,329 pts) & 19 registries (9,739 pts); 5 RCTs find PAH Rx assoc w/ 36% lower mortality/morbidity. Registry data shows better PAH survival since 2010 (73% vs 65% @3yrs) https://t.co/0BkO70AQfi

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of incident #RA in UK Clinical Practice registry shows recent prednisone >=7.5mg/d is assoc w/ hypertension in RA. In 17760 RA pts, 42% were Rx steroids; recent GC yielded a 17% increase in HTN (HR 1.17); only >7.5mg/D implicated https://t.co/qUKs2oZZUV https://t.co/pWmD4nKs6U

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Shenoi Suspect autoinflammatory Dz: patterned fevers MSK and skin involvement Serositis Other - aphthous ulcers, CNS (stroke, basal ganglia calcification,) ILD, LN, lipodystrophy) ethnicity (FMF or Mediterranean) Family Hx -- Testing options! #RWCS2021 @RheumNow @RWCSmtg https://t.co/DZk4hsxbk4

Dr. Rachel Tate uptoTate ( View Tweet)
Systemic Sclerosis Rapid Onset Pulmonary Arterial Hypertension Pulmonary Capillary Hemangiomatosis RWCS 2021 Poster Session by Dr. Jason Melehani, Stanford University https://t.co/wfxiY2VqcN

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×